ImClone News
Most Popular ImClone Story
Biogen Idec in play after Icahn makes his move
Biotech powerhouse Biogen Idec has brought in some of Wall Streets top dealmakers to explore a possible sale of the company, which would fetch well over $20 billion. In fact, says Biogen Idec, the... Read more...
Latest Headlines
- October 15, 2008
- October 6, 2008
- October 3, 2008
- October 2, 2008
- October 1, 2008
- September 29, 2008
- September 24, 2008
- September 23, 2008
- September 16, 2008
- September 12, 2008
- September 11, 2008
- September 10, 2008
- August 28, 2008
- August 21, 2008
- August 15, 2008
- August 11, 2008
- August 4, 2008
- July 31, 2008
- June 4, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
